secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-01-02T23:59:59+00:00
Accession:  0001628280-25-000005
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics appoints Jennifer Riley as Chief Strategy Officer; grants 150k stock option
--------------------------------------------------------------------------------

- Jennifer Riley appointed Chief Strategy Officer effective Jan 1, 2025; oversees corporate strategy and pipeline planning.
- Base salary $450,000; discretionary annual bonus target up to 40% of base salary.
- Received inducement stock option to purchase 150,000 shares, vesting over 4 years with 12-month cliff.
- Severance includes 9 months base salary (12 months if termination within 6 months after Change in Control) and full option vesting.
- Company advancing AVTX-009 (anti-IL-1β mAb) in LOTUS Phase 2 trial for hidradenitis suppurativa.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/0001628280-25-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828025000005/avtx-20250101.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer